The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease…

Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more

~Estimated

~$10 – $1,125

AstraZenecaNCT06465810

Phase 3

TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN)

The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality o…

Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PN

~Estimated

~$10 – $8,750

Alnylam PharmaceuticalsNCT07223203

Patisiran-LNP Pregnancy Surveillance Program

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisi…

Hereditary Transthyretin-mediated (hATTR) AmyloidosisPolyneuropathy

~Estimated

~$10 – $1,050

Alnylam PharmaceuticalsNCT05040373